Title | Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J |
Journal | Cancer Cell |
Volume | 22 |
Issue | 4 |
Pagination | 506-523 |
Date Published | 2012 Oct 16 |
ISSN | 1878-3686 |
Keywords | Animals, Cell Line, Tumor, Enhancer of Zeste Homolog 2 Protein, Gene Silencing, Histone Deacetylases, Histones, Humans, Lymphoma, B-Cell, Methylation, Mice, MicroRNAs, Polycomb Repressive Complex 2, Proto-Oncogene Proteins c-myc |
Abstract | We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 targeting miR-26a, and EZH2 induces MYC via inhibition of the MYC targeting miR-494 to create positive feedback. Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo. These findings define a MYC-mediated miRNA repression mechanism, shed light on MYC lymphomagenesis mechanisms, and reveal promising therapeutic targets for aggressive B-cell malignancies. |
DOI | 10.1016/j.ccr.2012.09.003 |
Alternate Journal | Cancer Cell |
PubMed ID | 23079660 |
PubMed Central ID | PMC3973134 |
Grant List | P30 CA076292 / CA / NCI NIH HHS / United States R01 CA134807 / CA / NCI NIH HHS / United States R01 CA137123 / CA / NCI NIH HHS / United States |
Related Lab:
Related Faculty:
Selina Chen-Kiang, Ph.D.